Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma

KRAS mutant (KRAS(mut)) lung adenocarcinoma is a refractory cancer without available targeted therapy. The current study explored the possibility to develop coxsackievirus type B3 (CVB3) as an oncolytic agent for the treatment of KRAS(mut) lung adenocarcinoma. In cultured cells, we discovered that C...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Haoyu, Liu, Huitao, de Silva, Tanya, Xue, YuanChao, Mohamud, Yasir, Ng, Chen Seng, Qu, Junyan, Zhang, Jingchun, Jia, William W.G., Lockwood, William W., Luo, Honglin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709373/
https://www.ncbi.nlm.nih.gov/pubmed/31463367
http://dx.doi.org/10.1016/j.omto.2019.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709373/
https://www.ncbi.nlm.nih.gov/pubmed/31463367
http://dx.doi.org/10.1016/j.omto.2019.07.003

Ejemplares similares